RxDoctor Payments Data

Blake Young, PA

Physician Assistant · Louisville, CONPI 1427727957

Payments from drug & device makers

$5,933in general payments, 2019–2025

Across 232 payments — averaging $25.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Jazz Pharmaceuticals Inc.$780
  • Sanofi$473
  • GSK$389
  • Regeneron Healthcare Solutions, Inc.$325
  • Axsome Therapeutics, Inc.$280
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,81498%
  • Education$1192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,933 in reported general payments places this provider in the 95th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$51,678
Medicare patients
498
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$43,226
Breo ElliptaFluticasone/Vilanterol24$11,975
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,163
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,060
Armodafinil22$1,377
Albuterol Sulfate HfaAlbuterol Sulfate30$1,054
Montelukast Sodium29$373
Doxepin Hcl16$254
Fluticasone Propionate22$218
Gabapentin15$119
Mirtazapine13$119
Trazodone Hcl14$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$389$55,20171 claims
AstraZenecaBreztri Aerosphere$1,476$8,16313 claims
Boehringer IngelheimStiolto Respimat$58$5,06011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Louisville

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →